[1] |
Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134:783-791.
|
[2] |
Pollack A, Pra AD. Androgen deprivation therapy combined with postoperative radiotherapy for prostate cancer management[J]. Lancet, 2024, 403:2353-2355.
|
[3] |
Kocianova E, Piatrikova V, Golias T. Revisiting the Warburg effect with focus on lactate[J]. Cancers (Basel), 2022,14:6028.doi: 10.3390/cancers14246028.
|
[4] |
Wang Y, Patti GJ. The Warburg effect: a signature of mitochondrial overload[J]. Trends Cell Biol, 2023, 33:1014-1020.
|
[5] |
Barba I, Carrillo-Bosch L, Seoane J. Targeting the warburg effect in cancer: where do we stand?[J]. Int J Mol Sci, 2024; 25:3142.doi: 10.3390/ijms25063142.
|
[6] |
Lebelo MT, Joubert AM, Visagie MH. Warburg effect and its role in tumourigenesis[J]. Arch Pharm Res, 2019, 42:833-847.
|
[7] |
Gonthier K, Weidmann C, Berthiaume L, et al. Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer[J]. Mol Oncol, 2023, 17:2109-2125.
|
[8] |
Zhang H, Liu S, Cai Z, et al. Down-regulation of ACACA suppresses the malignant progression of prostate cancer through inhibiting mitochondrial potential.[J] J Cancer, 2021, 12:232-243.
|
[9] |
Park IJ, Kim MJ, Park OJ, et al. Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation[J]. Cancer Lett, 2010, 298:88-98.
|
[10] |
Geng F, Guo D. SREBF1/SREBP-1 concurrently regulates lipid synthesis and lipophagy to maintain lipid homeostasis and tumor growth[J]. Autophagy, 2024, 20:1183-1185.
|
[11] |
Li X, Chen YT, Josson S, et al. MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells[J]. PLoS One, 2013, 8:e70987.doi: 10.3390/ijms25063142.
|
[12] |
Fukuda M, Ogasawara Y, Hayashi H, et al. Resvera-trol inhibits proliferation and induces autophagy by blocking SREBP1 expression in oral cancer cells[J]. Molecules, 2022,27:8250. doi: 10.3390/molecules27238250.
|
[13] |
He Y, Qi S, Chen L, et al. The roles and mechanisms of SREBP1 in cancer development and drug response[J]. Genes Dis, 2024, 11:100987.doi: 10.1016/j.gendis.2023.04.022.
|
[14] |
Fhu CW, Ali A. Fatty acid synthase: an emerging target in cancer[J]. Molecules, 2020, 25:3935. doi: 10.3390/molecules25173935.
|
[15] |
Zhang Y, Chen XN, Zhang H, et al. CDK13 promotes lipid deposition and prostate cancer progression by stimulating NSUN5-mediated m5C modification of ACC1 mRNA[J]. Cell Death Differ, 2023, 30:2462-2476.
|